Navigation Links
Amgen Announces KRAS Safety Update to U.S. Prescribing Information for Vectibix(R) (Panitumumab)
Date:7/17/2009

essly disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party payors, including gov
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Amgen Appoints Rebecca M. Henderson to the Companys Board of Directors
2. 34 Outstanding Teachers and Schools Receive $10,000 Amgen Award for Science Teaching Excellence
3. AUDIO from Medialink and Amgen: Experts Agree Infection in Cancer Patients Impacts Treatment Success
4. Amgen to Present at the Goldman Sachs Global Healthcare Conference
5. Loyola fellow receives Amgen grant to study treatments for older leukemia patients
6. Amgens Denosumab and Eli Lillys Forteo/Forsteo Will Drive Robust Annual Growth in the Osteoporosis Drug Market From 2013 to 2018
7. Amgen Highlights Data to Be Presented at ASCO
8. Amgen to Present at the Deutsche Bank 34th Annual Healthcare Conference
9. Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign
10. Amgens First Quarter 2009 Adjusted Earnings Per Share Decreased 4 Percent to $1.08
11. Amgen Announces Webcast of 2009 First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... CA (PRWEB) May 23, 2013 EnvirOasis, ... the contractor and ESCO market is pleased to announce ... Consortium (DLC) Listed LED products. EnvirOasis has been ... fixtures and retrofit kits and has recently brought ... LED (Light Emitting Diode) is energy efficient lighting ...
(Date:5/23/2013)... May 23 (HealthDay News) -- The sensation of itching ... traced back to a small molecule released in the ... mice. Researchers say this molecule, known as natriuretic ... the central nervous system. Ultimately, this signal is experienced ... and mice are similar, the researchers concluded that a ...
(Date:5/23/2013)... HealthDay Reporter , , THURSDAY, May 23 (HealthDay News) ... sharply, especially among Hispanic teens, according to a new government ... 15 to 19 dropped by nearly one half from 1991 ... teens to 31 births for every 1,000. From 2007 ... 25 percent, from 41.5 to about 31. During that ...
(Date:5/23/2013)... A shortage of a critical tuberculosis drug has hampered ... to contain the spread of the highly infectious lung ... was first used in 1951 and is one of ... first-line treatment for tuberculosis (TB). Patients must take the ... U.S. Centers for Disease Control and Prevention. However, ...
(Date:5/23/2013)... U.S. scientists have used virus isolated from a person ... whether the virus could infect and be transmitted between ... in influenza research, and efficient transmission of influenza virus ... the same process might occur in people. The research ... Allergy and Infectious Diseases, part of the National Institutes ...
Breaking Medicine News(10 mins):Health News:EnvirOasis Lighting Announces Energy Star and Design Lights Consortium LED Products 2Health News:Got an Itch? Mouse Study May Help Explain Why 2Health News:U.S. Teen Birth Rate Plummets: Report 2Health News:U.S. Teen Birth Rate Plummets: Report 3Health News:Shortage of Key Drug Hampering U.S. Efforts to Control TB: Report 2Health News:Ferrets, pigs susceptible to H7N9 avian influenza virus 2
... the No. 1 line-item cost of Medicare reimbursement and affects ... which can have devastating effects on the eye, affect 42 ... 80, and 68 percent of the population over the age ... University of Missouri professor has identified an important step in ...
... As millions of emails by,faithful Christians circulate around ... weeping image of Jesus Christ at Florida Hospital,s ... an explanation,today: "Jesus was weeping at the deplorable ... billion-dollar religious hospital,operation run by millionaire executives that ...
... effectiveness , , THURSDAY, April 17 (HealthDay News) -- The ... cells to their more plastic youthful condition in animal ... a possible new explanation for the antidepressant activity of ... it could be used to treat other conditions caused ...
... Dr. Thomas Gamba of Philadelphia to continue PDA,s efforts to improve ... ... Pennsylvania Dental,Association (PDA) recently installed Dr. Thomas W. Gamba of Philadelphia as,its ... improving patient access to oral health services will continue,to be a major ...
... MD, DrPH, Anna Cheskis Gelman and Murray Charles Gelman ... the Mailman School of Public Health and professor of ... 2008 Distinguished Investigator Award from NARSAD, the world,s leading ... Susser was selected for a study on famine and ...
... Celebrate Exemplary Nurses Who Support Chicagoland,s Medically ... when Sally Lemke lost,her nursing job providing prenatal care ... felt like a super star. That,s because the week,before ... her commitment and,passion for community health nursing and named ...
Cached Medicine News:Health News:MU researchers find clue to cataract formation 2Health News:Weeping Image of Jesus at Florida Hospital Explained 2Health News:Prozac Makes Old Brain Cells Young 2Health News:Prozac Makes Old Brain Cells Young 3Health News:New Pennsylvania Dental Association President Will Focus on Improving Access to Care 2Health News:New Pennsylvania Dental Association President Will Focus on Improving Access to Care 3Health News:Ezra Susser, MD, DrPH, receives Distinguished Investigator Award from NARSAD 2Health News:Chicagoland Super Star Community and Public Health Nurses - Now Is Your Chance to Win $25,000 2Health News:Chicagoland Super Star Community and Public Health Nurses - Now Is Your Chance to Win $25,000 3
(Date:5/23/2013)...  Hologic, Inc. (Hologic or the Company) (NASDAQ: ... and supplier of premium diagnostics, medical imaging systems ... the healthcare needs of women, today announced that ... clinical practice comparing breast cancer screening with Hologic,s ... mammography alone showed a significant reduction in recall ...
(Date:5/23/2013)... 23, 2013  BioElectronics Corporation (OTC Pink: BIEL), the ... on the FDA panel meeting for non-thermal shortwave diathermy: ... Pulsed Shortwave Therapy Meeting was held on May 21, ... The focus of the meeting was very narrow, in ... solely on the application of non-thermal shortwave diathermy for ...
(Date:5/23/2013)... YORK , May 23, 2013  Intercept Pharmaceuticals, ... stage biopharmaceutical company focused on the development and commercialization ... diseases, such as primary biliary cirrhosis, today announced that ... Chief Executive Officer, will present at the Deutsche Bank ... Boston on Wednesday, May 29, 2013 at ...
Breaking Medicine Technology:First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 2First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 3First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 4BioElectronics and Pulsed Shortwave Therapy Make Progress 2
... Significant Improvement in Cognitive Performance and Global Clinical Status ... ... 30 Forest Laboratories, Inc.,(NYSE: FRX ) presented today positive ... at the 2008,Alzheimer,s Association International Conference on Alzheimer,s Disease,(ICAD). The study ...
... 30 Wound Care Innovations, LLC,a subsidiary of ... today an evidence based study with a NE ... wound care collagen,product, CellerateRx(R), on diabetic venous ulcers. ... Control and Prevention, diabetes now,affects nearly 24 million ...
Cached Medicine Technology:New Data Highlight Positive Results of Namenda(R) (memantine HCl) Once-Daily Extended-Release Formulation 2New Data Highlight Positive Results of Namenda(R) (memantine HCl) Once-Daily Extended-Release Formulation 3New Data Highlight Positive Results of Namenda(R) (memantine HCl) Once-Daily Extended-Release Formulation 4Wound Management Technologies, Inc. Announces Agreement for Evidence Based Study for Diabetic Venous Ulcers 2
... the world leader in peel-away introducers. ... for permanent pacemaker and defibrillator lead ... implantation, and for temporary pacemaker insertions. ... Medical Peel-Away introducers includes the Di-Lock™ ...
The RX HERCULINK® PLUS Biliary Stent System is Guidant's high performance .014" guide wire compatible system. It is available in stent diameters of 4.0-6.5mm for the 12mm stent length and 4.0-7.0...
... Supreme and Response catheters comprise the ... available for electrophysiology procedures. Their advanced ... for superior torque response with a ... curves and French sizes, Supreme and ...
... Supreme and Response catheters comprise the ... available for electrophysiology procedures. Their advanced ... for superior torque response with a ... curves and French sizes, Supreme and ...
Medicine Products: